Fundraising FoxCancerVAX
Santa Barbara, US · Founded 2021 · Nevada corporation
Find your way into CancerVAX
Sign up to see every warm intro you have to CancerVAX
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CancerVAX team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CancerVax develops cancer therapeutics using lipid nanoparticle technology in partnership with Cytiva. The company is focused on creating nanoparticle-based treatments for cancer patients.
Founders & leadership
BE
Byron EltonExecutive
Board
CM
Carla MillerBoard director
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 of 2 rounds · 2023
▶$1MraisedOct 2024 · 1 investors · BiotechnologyRule 506(c)
▶$1MraisedOct 2024 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Carla MillerDirector
- Byron EltonExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1M
- Minimum investment
- $100K
- First sale
- Oct 2023
- Incorporated
- Corporation, Nevada, 2021
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
ImvaxImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
DynavaxDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
MimiVax, LLCMimiVax is a biopharmaceutical company developing immunotherapies for brain tumors, particularly glioblastoma, by harnessing the immune system to target cancer cells. The company's lead candidate, SurVaxM, is a peptide-based vaccine targeting survivin in cancer cells across multiple indications including glioblastoma, multiple myeloma, and neuroendocrine tumors.
VaccinexVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
CentivaxCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.
Companies working in the same space as CancerVAX.
In the news
Frequently asked questions
- What does CancerVAX do?
- CancerVax develops cancer therapeutics using lipid nanoparticle technology in partnership with Cytiva. The company is focused on creating nanoparticle-based treatments for cancer patients.
- How much funding has CancerVAX raised?
- CancerVAX has disclosed $1M raised across 1 of its 2 known rounds.
- Where is CancerVAX headquartered?
- CancerVAX is headquartered in Santa Barbara, US.